Expression of receptor activator of NF-κB ligand (RANKL) mRNA in human multiple myeloma cells

Journal of Cancer Research and Clinical Oncology

Volumn 130, Issue 8, 2004, Pages 469-474

  Heider, Ulrike ^a   Zavrski, Ivana ^a   Jakob, Christian ^a   Bängeroth, Katharina ^a   Fleissner, Claudia ^a   Langelotz, Corinna ^a   Possinger, Kurt ^a   Hofbauer, Lorenz C ^b   Viereck, Volker ^c   Sezer, Orhan ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

^c UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Multiple myeloma; Myeloma bone disease; Osteoprotegerin; RANK; RANKL

Indexed keywords

OSTEOCLAST DIFFERENTIATION FACTOR; PRIMER RNA; SYNDECAN 1;

ARTICLE; BONE ATROPHY; BONE MARROW CELL; CLINICAL ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

BONE MARROW; CARRIER PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MEMBRANE GLYCOPROTEINS; MULTIPLE MYELOMA; NF-KAPPA B; PLASMA CELLS; PROTEOGLYCANS; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RNA, MESSENGER; SYNDECAN-1; SYNDECANS;

EID: 4344625855     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Altamirano CV, Ma HJ, Parker KM, Glowalla A, Mikail AE, Sjak-Shie N, Vescio R, Berenson JR (2000) RANKL is expressed in multiple myeloma cell lines. Blood 96:365
2. Atkins GJ, Haynes DR, Geary SM, Loric M, Crotti TN, Findlay DM (2000) Coordinated cytokine expression by stromal and hematopoietic cells during human osteoclast formation. Bone 26:653-661
3. Ballester OF, Moscinski LC, Lyman GH, Chaney JV, Saba HI, Spiers AS, Klein C (1994) High levels of interleukin-6 are associated with low tumor burden and low growth fraction in multiple myeloma. Blood 83:1903-1908
4. Bekker PJ, Holloway D, Nakanishi A, Arrighi M, Leese PT, Dunstan CR (2001) The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res 16:348-360
5. Body JJ, Greipp P, Coleman RE, Facon T, Geurs F, Fermand JP, Harousseau JL, Lipton A, Mariette X, Williams CD, Nakanishi A, Holloway D, Martin SW, Dunstan CR, Bekker PJ (2003) A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 97[Suppl 3]:887-892
6. Callander NS, Roodman GD (2001) Myeloma bone disease. Semin Hematol 38:276-285
7. Choi SJ, Cruz JC, Craig F, Chung H, Devlin RD, Roodman GD, Alsina M (2000) Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma. Blood 96:671-675
8. Croucher PI, Shipman CM, Lippitt J, Perry M, Asosingh K, Hijzen A, Brabbs AC, van Beek EJ, Holen I, Skerry TM, Dunstan CR, Russell GR, Van Camp B, Vanderkerken K (2001) Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood 98:3534-3540
9. Eucker J, Eikel D, Heider U, Jakob C, Zavrski I, Gatz F, Mergenthaler HG, Jungclas H, Possinger K, Sezer O (2003) Liposomal daunorubicin (DaunoXome) in multiple myeloma: a modified VAD regimen using short-term infusion. Anticancer Drug 14:793-799
10. Farrugia AN, Atkins GJ, To LB, Pan B, Horvath N, Kostakis P, Findlay DM, Bardy P, Zannettino AC (2003) Receptor activator of nuclear factor-kappaB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo. Cancer Res 63:5438-5445
11. Giuliani N, Bataille R, Mancini C, Lazzaretti M, Barille S (2001) Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood 98:3527-3533
12. Heider U, Langelotz C, Jakob C, Zavrski I, Fleissner C, Eucker J, Possinger K, Hofbauer LC, Sezer O (2003) Expression of receptor activator of nuclear factor kappaB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma. Clin Cancer Res 9:1436-1440
13. Hofbauer LC, Gori F, Riggs BL, Lacey DL, Dunstan CR, Spelsberg TC, Khosla S (1999) Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology 140:4382-4389
14. Hofbauer LC, Neubauer A, Heufelder AE (2001a) Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases. Cancer 92:460-470
15. Hofbauer LC, Shui C, Riggs BL, Dunstan CR, Spelsberg TC, O'Brien T, Khosla S (2001b) Effects of immunosuppressants on receptor activator of kappaB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells. Biochem Biophys Res Commun 280:334-339
16. Hsu H, Lacey DL, Dunstan CR, Solovyev I, Colombero A, Timms E, Tan HL, Elliott G, Kelley MJ, Sarosi I, Wang L, Xia XZ, Elliott R, Chiu L, Black T, Scully S, Capparelli C, Morony S, Shimamoto G, Bass MB, Boyle WJ (1999) Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 96:3540-3545
17. Ikeda T, Kasai M, Utsuyama M, Hirokawa K (2001) Determination of three isoforms of the receptor activator of nuclear factor-kappaB ligand and their differential expression in bone and thymus. Endocrinology 142:1419-1426
18. Khosla S (2001) Minireview: the OPG/RANKL/RANK system. Endocrinology 142:5050-5055
19. Kinpara K, Mogi M, Kuzushima M, Togari A (2000) Osteoclast differentiation factor in human osteosarcoma cell line. J Immunoassay 21:327-340
20. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165-176
21. Lacy MQ, Donovan KA, Heimbach JK, Ahmann GJ, Lust JA (1999) Comparison of interleukin-1 beta expression by in situ hybridization in monoclonal gammopathy of undetermined significance and multiple myeloma. Blood 93:300-305
22. Mitsiades CS, Mitsiades N, Poulaki V, Hayashi T, Hideshima T, Podar K, LeBlanc R, Catley L, Tai Y, Chauhan D, Lin B, Schlossman R, Richardson PG, Munshi N, Treon SP, Anderson KC (2001) Receptor activator of nuclear factor-kB (RANK) ligand expression in human multiple myeloma cells. Blood 98[Suppl 1]:638
23. Nakashima T, Kobayashi Y, Yamasaki S, Kawakami A, Eguchi K, Sasaki H, Sakai H (2000) Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines. Biochem Biophys Res Commun 275:768-775
24. Niemöller K, Jakob C, Heider U, Zavrski I, Eucker J, Kaufmann O, Possinger K, Sezer O (2003) Bone marrow angiogenesis and its correlation with other disease characteristics in multiple myeloma in stage I versus stage II-III. J Cancer Res Clin Oncol 129:234-238
25. Oyajobi BO, Traianedes K, Yoneda T, Mundy GR (1998) Expression of Rank ligand (RankL) by myeloma cells requires binding to bone marrow stromal cells via an a4b1-VCAM-1 interaction. Bone 23:8180
26. Oyajobi BO, Garrett IR, Williams PJ, Yoneda T, Anderson DM, Mundy GR (2000) A soluble murine receptor activator of NF-kB-hman immunoglobulin fusion protein (RANK.Fc) inhibits bone resorption in a murine model of human multiple myeloma bone disease. J Bone Miner Res 15[Suppl 1]:1151
27. Pearse RN, Sordillo EM, Yaccoby S, Wong BR, Liau DF, Colman N, Michaeli J, Epstein J, Choi Y (2001) Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci USA 98:11581-11586
28. Plesner T, Boissy P, Dartell M, Norrild K, Hastrup N, Rasmussen M, Gaarsdal E, Delaissé JM, Anderson D (2001) Myeloma cells express and release Rank-ligand that promotes the generation of osteoclast-like cells. VIIIth International Myeloma Workshop, p 204
29. Roodman GD (2001) Biology of osteoclast activation in cancer. J Clin Oncol 19:3562-3571
30. Roux S, Meignin V, Quillard J, Meduri G, Guiochon-Mantel A, Fermand JP, Milgrom E, Mariette X (2002) RANK (receptor activator of nuclear factor-kappaB) and RANKL expression in multiple myeloma. Br J Haematol 117:86-92
31. Sati HI, Greaves M, Apperley JF, Russell RG, Croucher PI (1999) Expression of interleukin-1 beta and tumour necrosis factor-alpha in plasma cells from patients with multiple myeloma. Br J Haematol 104:350-357
32. Sezer O, Heider U, Jakob C, Eucker J, Possinger K (2002a) Human bone marrow myeloma cells express RANKL. J Clin Oncol 20:353-354
33. Sezer O, Heider U, Jakob C, Zavrski I, Eucker J, Possinger K, Sers C, Krenn V (2002b) Immunocytochemistry reveals RANKL expression of myeloma cells. Blood 99:4646-4647
34. Sezer O, Heider U, Zavrski I, Kuhne CA, Hofbauer LC (2003) RANK ligand and osteoprotegerin in myeloma bone disease. Blood 101:2094-2098
35. Shi SR, Tandon AK, Haussmann RR, Kalra KL, Taylor CR (1993) Immunohistochemical study of intermediate filament proteins on routinely processed, celloidin-embedded human temporal bone sections by using a new technique for antigen retrieval. Acta Otolaryngol 113:48-54
36. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander A, Van G, Tarpley J, Derby P, Lee R, Boyle WJ (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89:309-319
37. Standal T, Seidel C, Hjertner O, Plesner T, Sanderson RD, Waage A, Borset M, Sundan A (2002) Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells. Blood 100:3002-3007
38. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ (1999) Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 20:345-357
39. Terpos E, Politou M, Rahemtulla (2003) New insights into the pathophysiology and management of bone disease in multiple myeloma. Br J Haematol 123:758-769
40. Viereck V, Emons G, Lauck V, Frosch KH, Blaschke S, Grundker C, Hofbauer LC (2002) Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. Biochem Biophys Res Commun 291:680-686
41. Westin JS, Ljunghall S, Nilsson K, Ljunggren O (1999) Human multiple myeloma cell lines express mRNA for osteoclast differentiation factor. J Bone Miner Res 14[Suppl 1]:S225
42. Yaccoby S, Pearse RN, Johnson CL, Barlogie B, Choi Y, Epstein J (2002) Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. Br J Haematol 116:278-290
43. Zavrski I, Naujokat C, Niemöller K, Jakob C, Heider U, Langelotz C, Fleissner C, Eucker J, Possinger K, Sezer O (2003) Proteasome inhibitors induce growth inhibition and apoptosis in myeloma cell lines and in human bone marrow myeloma cells irrespective of chromosome 13 deletion. J Cancer Res Clin Oncol 129:383-391